Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study (Q42702371)
Jump to navigation
Jump to search
scientific article published on 3 March 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study |
scientific article published on 3 March 2015 |
Statements
1 reference
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study (English)
1 reference
John J P Kastelein
1 reference
Joost Besseling
1 reference
Sukrut Shah
1 reference
Jean Bergeron
1 reference
Gisle Langslet
1 reference
G Kees Hovingh
1 reference
Naab Al-Saady
1 reference
Michiel Koeijvoets
1 reference
John Hunter
1 reference
Amy O Johnson-Levonas
1 reference
Jennifer Fable
1 reference
Aditi Sapre
1 reference
Yale Mitchel
1 reference
3 March 2015
1 reference
Identifiers
1 reference